Glucophage ®

Metformin (INN) (pronounced /mɛtˈfɔrmɪn/; originally sold as Glucophage) is an oral anti-diabetic drug in the biguanide class. It is the first-line drug of choice for the treatment of type 2 diabetes, particularly in overweight and obese people and those with normal kidney function.[1][2][3] Evidence is also mounting for its efficacy in gestational diabetes, although safety concerns still preclude its widespread use in this setting. It is also used in the treatment of polycystic ovary syndrome and has been investigated for other diseases where insulin resistance may be an important factor.


Metformin has an oral bioavailability of 50–60% under fasting conditions, and is absorbed slowly.[95][96] Peak plasma concentrations (Cmax) are reached within one to three hours of taking immediate-release metformin and four to eight hours with extended-release formulations.[95][96] The plasma protein binding of metformin is negligible, as reflected by its very high apparent volume of distribution (300–1000 L after a single dose). Steady state is usually reached in one or two days.[95]
Metformin is not metabolized. It is cleared from the body by tubular secretion and excreted unchanged in the urine; metformin is undetectable in blood plasma within 24 hours of a single oral dose.[95][97] The average elimination half-life in plasma is 6.2 hours.[95] Metformin is distributed to (and appears to accumulate in) red blood cells, with a much longer elimination half-life: 17.6 hours[95] (reported as ranging from 18.5 to 31.5 hours in a single-dose study of non-diabetic people).[97]

Mechanism of action

Metformin improves hyperglycemia primarily through its suppression of hepatic glucose production (hepatic gluconeogenesis).[78] The “average” person with type 2 diabetes has three times the normal rate of gluconeogenesis; metformin treatment reduces this by over one third.[98] Metformin activates AMP-activated protein kinasefats;[99] activation of AMPK is required for metformin’s inhibitory effect on the production of glucose by liver cells.[100] Research published in 2008 further elucidated metformin’s mechanism of action, showing that activation of AMPK is required for an increase in the expression of SHP, which in turn inhibits the expression of the hepatic gluconeogenic genes PEPCK and Glc-6-Pase.[101] Metformin is frequently used in research along with AICAR as an AMPK agonist. The mechanism by which biguanides increase the activity of AMPK remains uncertain; however, research suggests that metformin increases the amount of cytosolic AMP (as opposed to a change in total AMP or total AMP/ATP).[102] (AMPK), a liver enzyme that plays an important role in insulin signaling, whole body energy balance, and the metabolism of glucose and
In addition to suppressing hepatic glucose production, metformin increases insulin sensitivity, enhances peripheral glucose uptake, increases fatty acid oxidation,[103]gastrointestinal tract. Increased peripheral utilization of glucose may be due to improved insulin binding to insulin receptors.[104] AMPK probably also plays a role, as metformin administration increases AMPK activity in skeletal muscle.[105] AMPK is known to cause GLUT4 deployment to the plasma membrane, resulting in insulin-independent glucose uptake. Some metabolic actions of metformin do appear to occur by AMPK-independent mechanisms; a 2008 study found that “the metabolic actions of metformin in the heart muscle can occur independent of changes in AMPK activity and may be mediated by p38 MAPK– and PKC-dependent mechanisms.”[106] and decreases absorption of glucose from the


The H2-receptor antagonist cimetidine causes an increase in the plasma concentration of metformin, by reducing clearance of metformin by the kidneys;[107] both metformin and cimetidine are cleared from the body by tubular secretion, and both, particularly the cationic (positively charged) form of cimetidine, may compete for the same transport mechanism.[95] A small double-blind, randomized study found the antibiotic cefalexin to also increase metformin concentrations by a similar mechanism;[108] theoretically, other cationic medications may produce the same effect.[95]

When prescribed appropriately, metformin causes few adverse effects—the most common is gastrointestinal upset—and, unlike many other anti-diabetic drugs, does not cause hypoglycemia if used alone. Lactic acidosis (a buildup of lactate in the blood) can be a serious concern in overdose and when it is prescribed to people with contraindications, but otherwise, there is no significant risk. Metformin helps reduce LDL cholesterol and triglyceride levels and is not associated with weight gain, and is the only anti-diabetic drug that has been conclusively shown to prevent the cardiovascular complications of diabetes. As of 2009[update], metformin is one of only two oral anti-diabetics in the World Health Organization Model List of Essential Medicines (the other being glibenclamide).[4]
First synthesized and found to reduce blood sugar in the 1920s, metformin was forgotten for the next two decades as research shifted to insulin and other anti-diabetic drugs. Interest in metformin was rekindled in the late 1940s after several reports that it could reduce blood sugar levels in people, and in 1957, French physician Jean Sterne published the first clinical trial of metformin as a treatment for diabetes. It was introduced to the United Kingdom in 1958, Canada in 1972, and the United States in 1995. Metformin is now believed to be the most widely prescribed anti-diabetic drug in the world; in the United States alone, more than 40 million prescriptions were filled in 2008 for its generic formulations.[5][6]


The biguanide class of anti-diabetic drugs, which also includes the withdrawn agents phenformin and buformin, originates from the French lilac (Galega officinalis), a plant used in folk medicine for several centuries.[7]
Metformin was first described in the scientific literature in 1922, by Emil Werner and James Bell, as a side product in the synthesis of N,N-dimethylguanidine.[8] In 1929, Slotta and Tschesche discovered its sugar-lowering action in rabbits, noting that it was the most potent of the biguanide analogs they studied.[9] This result was completely forgotten as other guanidine analogs, such as the synthalins, took over, and were themselves soon overshadowed by insulin.[10]
Interest in metformin, however, picked up at the end of the 1940s. In 1950, metformin, unlike some other similar compounds, was found not to decrease blood pressure and heart rate in animals.[11] That same year, a prominent Philippine physician, Eusebio Y. Garcia,[12] used metformin (he named it Fluamine) to treat influenza; he noted that the drug “lowered the blood sugar to minimum physiological limit” in treated patients and was non-toxic. Garcia also believed metformin to have bacteriostatic, antiviral, antimalarial, antipyretic and analgesic actions.[13] In a series of articles in 1954, Polish pharmacologist Janusz Supniewski[14] was unable to confirm most of these effects, including lowered blood sugar; he did, however, observe some antiviral effects in humans.[15][16]
While training at the Hôpital de la Pitié, French diabetologist Jean Sterne studied the antihyperglycemic properties of galegine, an alkaloid isolated from Galega officinalis, which is structurally related to metformin and had seen brief use as an anti-diabetic before the synthalins were developed.[5] Later, working at Laboratoires Aron in Paris, he was prompted by Garcia’s report to re-investigate the blood sugar lowering activity of metformin and several biguanide analogs. Sterne was the first to try metformin on humans for the treatment of diabetes; he coined the name “Glucophage” (glucose eater) for the drug and published his results in 1957.[5][10]
Metformin became available in the British National Formulary in 1958. It was sold in the UK by a small Aron subsidiary called Rona. [17]
Broad interest in metformin was not rekindled until the withdrawal of the other biguanides in the 1970s. Metformin was approved in Canada in 1972,[18] but did not receive approval by the U.S. Food and Drug Administration (FDA) for Type 2 diabetes until 1994.[19] Produced under license by Bristol-Myers Squibb, Glucophage was the first branded formulation of metformin to be marketed in the United States, beginning on March 3, 1995.[20] Generic formulations are now available in several countries, and metformin is believed to have become the most widely prescribed anti-diabetic drug in the world.[5]

Treatment of diabetes

The main use for metformin is in the treatment of diabetes mellitus type 2, especially in overweight people. In this group, over 10 years of treatment, metformin reduced diabetes complications and overall mortality by about 30% when compared with insulin and sulfonylureas (glibenclamide and chlorpropamide) and by about 40% when compared with the group only given dietary advice.[21] This difference held in the patients who were followed for 5–10 years after the study.[22] In addition, metformin had no effect on body weight: over the 10-year treatment period, the metformin group gained about 1 kg, the same as the dietary advice group, while the sulfonylureas group gained 3 kg, and the insulin group, 6 kg.[21][23] As metformin affords a similar level of blood sugar control to insulin and sulfonylureas, it appears to decrease mortality primarily through decreasing heart attacks, strokes and other cardiovascular complications.
Unlike the other most-commonly prescribed class of oral diabetes drugs, the sulfonylureas, metformin does not induce hypoglycemia when taken alone and used at recommended dosages.[24][25] Hypoglycemia during intense exercise has been documented, but is extremely rare.[26] It is also not associated with weight gain, and modestly reduces LDL and triglyceride levels.[24][25]
Several epidemiological and case-controlled studies found that diabetics using metformin may have lower cancer risk in comparison to those using other sugar-lowering medications. The causes of this phenomenon are unclear, and the results require confirmation in controlled studies.[27]

Off-label use

Metformin is also being used increasingly in polycystic ovary syndrome (PCOS),[28] non-alcoholic fatty liver disease (NAFLD)[29] and premature puberty,[30] three other diseases that feature insulin resistance; these indications are still[update] considered experimental. The benefit of metformin in NAFLD has not been extensively studied and may be only temporary;[31] although some randomized controlled trials have found significant improvement with its use, the evidence is still insufficient.[32][33]


Metformin treatment of people at risk for type 2 diabetes may decrease their chances of developing the disease, although intensive physical exercise and dieting work significantly better for this purpose. In a large U.S. study known as the Diabetes Prevention Program, participants were divided into groups and given either placebo, metformin, or lifestyle intervention, and followed for an average of three years. The intensive program of lifestyle modifications included a 16-lesson training on dieting and exercise followed by monthly individualized sessions with the goals to decrease the body weight by 7% and engage in a physical activity for at least 150 minutes per week. The incidence of diabetes was 58% lower in the lifestyle group and 31% lower in those given metformin. Among people under 44 years of age and those with a body mass index greater than 35, lifestyle modification was no more effective than metformin, and for those older than 60, metformin was no better than placebo in preventing diabetes.[34] After ten years, the incidence of diabetes was 34% lower in the group of participants given diet and exercise and 18% lower in those given metformin.[35] It is unclear whether metformin slowed down the progression of pre-diabetes to diabetes (true preventive effect), or the decrease of diabetes in the treated population was simply due to its blood-lowering action (treatment effect).[36]

Polycystic ovary syndrome

Antidiabetic therapy has been proposed as a treatment for polycystic ovary syndrome, a condition frequently associated with insulin resistance, since the late 1980s.[37]University of the Andes, Venezuela.[38][39] The United Kingdom’s National Institute for Health and Clinical Excellence recommended in 2004 that women with PCOS and a body mass index above 25 be given metformin for anovulation and infertility when other therapy has failed to produce results.[40] However, two large clinical studies completed in 2006–2007 returned mostly negative results, with metformin being no better than placebo and metformin-clomifene combination no better than clomifene alone.[41][42] Reflecting this, subsequent reviews noted that large randomized control trials have in general not shown the promise suggested by the early small studies. U.K. and international clinical practice guidelines do not recommend metformin as a first-line treatment[43] or do not recommend it at all, except for women with glucose intolerance.[44] The guidelines suggest clomiphene as the first medication option and emphasize lifestyle modification independently from the drug treatment. The use of metformin in PCOS was first reported in 1994, in a small study conducted at the
In a dissenting opinion, a systematic review of four head-to-head comparative trials of metformin and clomifene found them equally effective for infertility.[45] A BMJ editorial noted that four positive studies of metformin were in patients who did not respond to clomifene, while the population in the negative studies was drug-naive or uncontrolled for the previous treatment. The editorial suggested that metformin should be used as a second-line drug if clomifene treatment fails.[46] Another review recommended metformin unreservedly as a first-line treatment option because it has positive effects not only on anovulation but also on insulin resistance, hirsutism, and obesity often associated with PCOS.[47] A large Cochrane Collaboration review of 27 randomized clinical trials found that metformin improves ovulation and pregnancy rates, particularly when combined with clomifene, but is not associated with any increase in the number of live births.[48]
The design of the negative trials may be one of the explanations for the contradictory results. For example, using live birth rate instead of pregnancy as the end point may have biased some trials against metformin, which works slower than clomifene.[49] Another explanation may be different efficacy of metformin in different populations of patients. The negative trials contained large percent of obese and previously untreated patients whose response to metformin may be weaker.[49]

Gestational diabetes

Several observational studies and randomized controlled trials have found that metformin is as effective and safe as insulin for the management of gestational diabetes,[50][51][52] and a small case-control study has suggested that the children of women given metformin instead of insulin may be healthier in the neonatal period.[53][54] Nonetheless, several concerns have been raised regarding studies published thus far, and evidence on the long-term safety of metformin for both mother and child is still lacking.

Combinations with other drugs

Metformin is sometimes prescribed to type 2 diabetes patients in combination with rosiglitazone. This drug actively reduces insulin resistance, complementing the action of the metformin. In 2002, the two drugs were combined into a single product, Avandamet, marketed by GlaxoSmithKline.[59] In 2005, all current stock of Avandamet was seized by the FDA and removed from the market, after inspections showed the factory where it was produced was violating Good Manufacturing Practices.[60] The drug pair continued to be prescribed separately in the absence of Avandamet, which was available again by the end of that year.
In the United States, metformin is also available in combination with pioglitazone (trade name Actoplus Met), the sulfonylureas glipizide (trade name Metaglip) and glibenclamide (known as glyburide in the United States, trade name Glucovance), the dipeptidyl peptidase-4 inhibitor sitagliptin (trade name Janumet), and the meglitinide repaglinide (PrandiMet). Generic formulations of metformin/glipizide and metformin/glibenclamide are available. A generic formulation of metformin/rosiglitazone from Teva has received tentative approval from the FDA, and is expected to reach the market in early 2012.[61]


Metformin is contraindicated in people with any condition that could increase the risk of lactic acidosis, including kidney disorders (creatinine levels over 150 μmol/l,[62] although this is an arbitrary limit), lung disease and liver disease. According to the prescribing information, heart failure, in particular, unstable or acute congestive heart failure increases risk of lactic acidosis with metformin.[63] A 2007 systematic review of controlled trials, however, suggested that metformin is the only anti-diabetic drug not associated with any measurable harm in people with heart failure, and that it may reduce mortality in comparison with other anti-diabetic agents.[64]
It is recommended that metformin be temporarily discontinued before any radiographic study involving iodinated contrast (such as a contrast-enhanced CT scan or angiogram), as contrast dye may temporarily impair kidney function, indirectly leading to lactic acidosis by causing retention of metformin in the body.[65][66] It is recommended that metformin be resumed after two days, assuming kidney function is normal.[65][66]

Adverse effects

The most common adverse effect of metformin is gastrointestinal upset, including diarrhea, cramps, nausea, vomiting and increased flatulence; metformin is more commonly associated with gastrointestinal side effects than most other anti-diabetic drugs.[25] The most serious potential side effect of metformin use is lactic acidosis; this complication is very rare, and the vast majority of these cases seem to be related to comorbid conditions such as impaired liver or kidney function, rather than to the metformin itself.[67]
Metformin has also been reported to decrease the blood levels of thyroid-stimulating hormone in patients with hypothyroidism,[68] and, in men, lutenizing hormone and testosterone.[69][70] The clinical significance of these changes is still unknown.